A stylized globe graphic, with the EU area emphasized
ISIDORe project home / Services / Support for Vaccine development

Support for vaccine development

Boost the development of your vaccine candidate.

SERVICES PROVIDED TO YOU BY: Transvac, VetBioNet & Instruct

Vaccine development requires a combination of specialized skills and technical capacities not readily available at a single organization. Find all those skills and capacities in our catalogue.

Please note that all the in vivo models for vaccine efficacy studies are available in the IN VIVO MODELS services.

VACCINE PLATFORM TECHNOLOGIES: SCREENING, EXPRESSION AND OPTIMISATION

Provided to you by: Transvac & VetBioNet

Contacts
Catarina LUIS
Catarina.Luis@euvaccine.eu

William MARTIN
William.Martin@euvaccine.eu

  • Cross-platform screening and pre‑clinical optimization with access to vaccine platform technologies (including proteins, viral like particles, viral vectors) and expression systems (including mammalian and insect cells)
    Small-to-medium-scale (mg-scale) expression and purification of antigens from multiple candidate constructs. Expression can be compared in multiple expression systems, including P. pastoris, L. lactis, E. coli; Nicotiana; and constitutive/transient expression in mammalian/ insect cells. Vaccine formats include design and production of viral vector vaccines, Adenovirus (human and chimpanzee) and MVA
  • Custom construction of nanoparticles based on respiratory syncytial virus nucleoprotein as booster for antigen presentation
  • Custom construction of recombinant viral proteins in HEK Freestyle cells
  • Custom construction of recombinant vaccine
    Two available backbones (non-deleted or E1-deleted genomes) derived from the Manhattan vaccine strain of the canine adenovirus type 2 (CAV-2)
  • Design and development of nanoparticle-based mucosal vaccine systems for SARS-CoV-2 or other respiratory pathogens
  • Expression and purification of SARS-CoV structural proteins for vaccination and in vitro diagnostics
    Expression systems available: E. coli, baculovirus

VACCINE PROCESS DEVELOPMENT & PRODUCTION

Provided to you by: Transvac

Contacts
Catarina LUIS
Catarina.Luis@euvaccine.eu

William MARTIN
William.Martin@euvaccine.eu

  • Pre‑clinical GLP production services
  • Development and implementation of analytical methods for product characterization and process control and monitoring
  • GMP manufacturing of starting materials
  • GMP manufacturing of clinical materials

VACCINE ADJUVANTS & FORMULATION

Provided to you by: Transvac

Contacts
Catarina LUIS
Catarina.Luis@euvaccine.eu

William MARTIN
William.Martin@euvaccine.eu

  • Development and characterisation of vaccine formulations with liposomal adjuvants CAF01 and CAF09b.
  • Provision of CAF01 and CAF09b adjuvants at GMP grade for use in clinical studies.
  • Formulation development and characterisation
  • Upscaling of emulsion and liposome-based adjuvants from lab-scale to pilot-scale
  • Technological transfer of pilot scale process; manufacturing parameters of emulsion and liposome adjuvants and manufacturing of preclinical tox batch
  • Provision of emulsion and liposome-based adjuvants at GMP grade for use in clinical studies
  • Formulation and characterisation of vaccine candidates paired with mucosal or parenteral adjuvants

STRUCTURAL & CHEMICAL CHARACTERIZATION OF VACCINES AND VACCINE ANTIGENS

Provided to you by: Instruct & the Joint Research Centre of the European Commission

Contact
Pauline AUDERGON
pauline@instruct-eric.org

  • Structural characterisation of vaccine antigens (bound or unbound) – see also ANALYTICAL SERVICES
    • X-ray methods
      • From Sample to X-ray diffraction pipelines
      • XChem Fragment Screening
      • Online crystallography pipeline for Rapid structural characterization of antigens based on CrystalDirect technology
    • Bio-SAXS, solution
    • NMR technologies, solid state
      • Atomic level characterization and/or interactions (IDP, proteins, host’s proteins, nucleic acids, etc);
      • Quality assurance via NMR (HOS of vaccines, antibodies, antigens/adjuvants);
      • Fast fingerprinting/profiling via NMR metabolomics on blood (serum, plasma) and urine
      • Fragment-screening by NMR
    • Cryo-EM (single particle analysis)
      • Scanning electron microscopy (SEM) -Transmission electron microscopy (TEM)
      • Cryogenic electron microscopy (Cryo-EM)
      • Electron tomography
    • Cryo-ET (in combination with EuBi for correlative EM/light microscopy)
  • Physico-chemical and in-vitro characterization of adjuvant and nanovaccines (such as LNP-mRNA)
    Physical attributes (size distribution, particle concentration). Chemical (composition, free/bound cargo; cargo release kinetic); Stability (aggregation, time stability; mRNA/antigen integrity). In vitro toxicity (endotoxin contamination, cytotoxicity, immunotoxicity)
  • Identification and measurement of key quality attributes of nanovaccines